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Niemann-Pick disease type C clinical database:
cognitive and coordination deficits are early
disease indicators
Miriam Stampfer1, Susanne Theiss1, Yasmina Amraoui2, Xuntian Jiang3, Sigrid Keller2, Daniel S Ory3,
Eugen Mengel2, Christine Fischer1 and Heiko Runz1,4*
Abstract
Background: The neurodegenerative lysosomal storage disorder Niemann-Pick disease type C (NP-C) is
characterized by a broad clinical variability involving neurological, psychiatric and systemic signs. Diverse patterns of
disease manifestation and progression considerably delay its diagnosis. Here we introduce the NP-C clinical
database (NPC-cdb) to systematically obtain, store and analyze diagnostic and clinical findings in patients with NP-C.
We apply NPC-cdb to study NP-C temporal expression in a large German-Swiss patient cohort.
Methods: Current and past medical history was systematically acquired from 42 patients using tailored questionnaires.
Manifestation of 72 distinct neuropsychiatric signs was modeled over the course of disease. The sequence of disease
progression was re-constructed by a novel clinical outcome scale (NPC-cdb score).
Results: The efficiency of current clinical diagnostic standards negatively correlates with duration of disease
(p<3.9x10-4), suggesting insufficient sensitivity in patients early in the disease process. Neurological signs considered as
typical for NP-C were frequent (e.g., cognitive impairment 86%, ataxia 79%, vertical supranuclear gaze palsy 76%) and
their presence co-occurred with accelerated diagnosis. However, less specific neuropsychiatric signs were reported to
arise considerably more early in the disease process (e.g., clumsiness -4.9±1.1 y before diagnosis). Most patients showed
a steady disease progression that correlated with age at neurological onset. However, a distinct subcohort (n=6) with
initially steadily progressing disease later showed a 2.9-fold accelerated progression that was associated with the onset
of seizures (p<7x10-4), suggesting seizures as predictive for a poor prognosis.
Conclusions: Considering early, but less specific neuropsychiatric signs may accelerate the path to diagnosing NP-C
in a patient.
Keywords: Cholesterol, Clinical repository, Genotype-phenotype, Neurodegenerative disease, Oxysterols
Background
Niemann-Pick disease type C (NP-C; OMIM#257220;
OMIM#607625) is a progressive lysosomal storage disorder
with an estimated incidence of 1:120,000 live births [1-4].
Autosomal-recessive inheritance of mutations in either of
two genes, NPC1 and NPC2, are known causes [5,6]. Clin-
ical features of NP-C encompass a wide spectrum of sys-
temic, neurological and psychiatric signs. Systemic disease
involves (hepato)splenomegaly and a risk for liver failure in
affected infants. Characteristic neurological manifestations
of NP-C are unrelated to visceral disease and include
oculo-motor abnormalities (impaired saccadic eye move-
ments, vertical supranuclear gaze palsy (VSGP)), cerebellar
signs (ataxia, dystonia/dysmetria, dysarthria and dysphagia)
and gelastic cataplexy. Upon disease progression, any sort
of epileptic seizure may occur. Most patients develop cog-
nitive impairment progressing to dementia. Schizophrenia-
like psychosis is common in adults. Additionally, NP-C
patients may show a multitude of less frequent and less
specific symptoms [1,3,4].
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The variable clinical picture, manifestation at different
ages and diverse patterns of disease progression may delay
the diagnosis NP-C for several years. The advent of plasma
oxysterols as novel NP-C screening markers may help to
partially reduce this diagnostic delay [7]. However, a com-
prehensive clinical assessment is considered as key to un-
ambiguously assign the diagnosis [8]. An early diagnosis
thus necessitates a better understanding of which clinical
signs occur particularly early and at which sequence in the
course of disease. This is particularly true for neurological
symptoms as the major determinant of disease progression
[4] and response to treatment [8-10]. To date, several stud-
ies have addressed how NP-C develops over time [11-18].
However, only rarely the disease spectrum has been ana-
lyzed comprehensively. Moreover, due to the rarity of
NP-C, individual studies typically miss the statistical power
to allow for generalization of their respective findings.
Here we have generated infrastructure to systematically
assess, store and share NP-C specific clinical datasets as a
resource for future large-scale collaborative studies. We
apply our tools for a pilot study assessing the expression
of NP-C in a large German-Swiss patient cohort. We iden-
tify distinct patterns of disease progression that correlate
with specific neurologic manifestations. Moreover, our
data suggest that an early diagnosis will profit from re-
specting less specific neuropsychiatric signs of NP-C.
Methods
Participants
This is a two-center cross-sectional analysis of patient
data. Data were acquired on 42 NP-C patients resident
in Germany or Switzerland that (i.) at start of the study
were still alive and (ii.) had been diagnosed within the
past six years and/or long-term comprehensive medical
records were available. Diagnosis NP-C was assured by
sequencing of NPC1 (NM_000271) and NPC2 (NM_00
6432) genes, complemented by filipin staining of cul-
tured skin fibroblasts as described [19,20] (Figure 1).
Haplotypes of all patients (including six novel NPC1 var-
iants: c.1112delT1n+del, p.W381C, p.A558T, c.2197_21
98insT, p.M1001V and p.F1167C) were entered into the
online NP-C gene variation database (NPC-db; [21]). Data
were assessed and evaluated by two clinical experts. Pa-
tients were diagnosed and/or followed-up at the Institute
of Human Genetics Heidelberg, Germany and the Center
for Lysosomal Storage Disorders Mainz, Germany.
Standard protocol approvals, registrations, and
patient consent
All subjects were enrolled with either their own or their
representatives signed consent as covered by the IRB ap-
proval S-032/2012 from Heidelberg University. The study
protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki.
Data collection and assessment
Data were acquired over a period of 30 months (2009-
2011) from personal interviews with the families and
own or externally contributed longitudinal medical re-
cords. Neurological status of each patient at the time of
the interview was assessed by clinical examination. Inter-
view data were obtained with a customized question-
naire consisting of 270 questions on medical history,
including 44 on diagnosis (Additional file 1). This ques-
tionnaire assisted to acquire data in a standardized for-
mat that allowed for systematic comparisons between
patients. Data were then transferred as fixed terms and/
or quantifiable parameters into an electronic Microsoft
Office AccessW-based database termed NP-C clinical
database (NPC-cdb) (Additional file 2).
Statistical analysis
For each of the 72 neuropsychiatric symptoms assessed,
time from onset of neurological disease to occurrence of
the respective symptom was documented. For patients
not showing a respective symptom, time until the last
visit was used as censored observation. Mean/median
(incl. 95% confidence interval, 95%CI) timespan until oc-
currence was estimated by non-parametric censored
Kaplan-Meier survival analysis using SPSS V20 (IBM
Corp. Armonk, NY, USA). Fisher’s exact test was used to
test for statistical significance of categorical data. Based
on published data [8] sensitivity of the NP-C Suspicion
Index tool was estimated as 95%. For association ana-
lyses of disease progression with seizures, relative NPC-
cdb scores (cleaned from seizure-associated score points)
two years before and after the first seizure event were
determined and compared to disease progression in the
cohort where no seizures had yet occurred.
NPC-cdb score
NPC-cdb aims to document the comprehensive past and
present clinical information available per patient. Based
on our own experience and previous estimates [8,13,17],
each symptom was subjectively scored according to its
relative contribution to the general impairment of a pa-
tient (for guidelines on how to evaluate individual symp-
toms using the NPC-cdb score, see Additional file 3). A
composite score (NPC-cdb score) was generated by adding
up all past and current scores with each symptom contrib-
uting as a summand. Longitudinal scores were generated
by reconstructing past medical history from interview re-
sults and clinical records. Reliability of the NPC-cdb score
to adequately reflect NP-C severity was assured by as-
sessing disease progression in all our patients also with the
NPC clinical severity scale [17] (excluding evaluation of
hearing, since required tests had been conducted only in
few patients).













































































































































































































































012 0 0 5 f 41 na 92 271 2 p.P691S SSD c.2279_2281TCTdel - -/- -/- -/- -/- -/- na NAD NAD
028 0 1 1 f 0 cl. na na 2 NAD - NAD - -/- -/- +/- -/- -/- na p.E20X p.E118X
007 1 0 5 f 20 cl. 63 144 2 c.352_353delAG - c.353_353delAG - -/- +/+ +/+ +/+ +/+ na NAD NAD
005 2 5 8 f 170 na 153 391 2 p.H1016L Cys-rich p.I1061T Cys-rich +/- -/- +/- -/- -/- na NAD NAD
024 2 2 4 f 170 cl. 88 287 1 p.S940L Cys-rich NAD - -/- -/- -/- -/- -/- na NAD NAD
026 2 9 10 m 120 na na na 2 p.P1007A Cys-rich p.R958Q Cys-rich -/- +/- +/- +/- +/- p.P532L NAD NAD
003 3 5 8 m 90 na 77 209 2 p.A926V Cys-rich p.P1007A Cys-rich -/- +/+ +/+ +/+ +/+ na NAD NAD
002 4 4 8 m 20 cl. 89 270 2 p.I1061T Cys-rich p.E1188X - +/- +/- +/+ -/- +/- na NAD NAD
017 4 14 29 m 150 cl. na na 1 p.R116X - NAD - na na na na na p.P237S NAD NAD
029 4 7 12 m 221 indiff. na na 2 p.R934X Cys-rich p.P1007A Cys-rich +/- +/- +/+ +/- +/- na NAD NAD
031 4 10 12 m 190 var. na na 2 p.P1007A Cys-rich IVS7+5 (c.960g>a) - +/- -/- +/- +/- +/- na NAD NAD
035 4 9 9 f 241 cl. 67 194 1 p.M1001V - NAD - -/- +/+ +/+ +/+ +/+ na NAD NAD
037 4 10 10 f 261 na na na 2 p.P1007A Cys-rich p.L1244P - -/- -/- -/- -/- -/- na NAD NAD
004 5 5 10 f 60 cl. 75 212 1 p.P401L - NAD - +/- -/- +/- -/- -/- na NAD NAD
022 5 10 20 m 220 na 92 238 2 p.W381C - c.1112delT1n+del - na +/+ +/- na na p.P237S NAD NAD
044 5 30 31 m 217 na na na 2 p.R978C Cys-rich delX1-X6 - +/+ +/+ +/+ +/+ +/+ na NAD NAD
001 6 13 14 m 160 cl. na na 2 p.S954L Cys-rich
IVS23+1g>a
(c.3591+1g>a) - -/- +/- +/- +/- +/- na NAD NAD
008 6 5 12 f 40 var. 51 144 2 p.S940L Cys-rich p.P1007A Cys-rich -/- +/+ +/+ +/+ +/+ na NAD NAD
038 6 17 17 m 271 na na na 2 p.I1061T Cys-rich p.F1167C - +/- +/- +/+ +/- -/- na NAD NAD
039 6 28 28 f 176 cl. na na 2 p.A558T - c.2197insT - -/- +/- +/- +/- +/- na NAD NAD
016 7 16 24 f 150 na na na 2 p.P1007A Cys-rich p.I1061T Cys-rich -/- -/- -/- -/- -/- na NAD NAD
025 8 18 19 m 216 cl. na na 2 p.S734I SSD p.S954L Cys-rich -/- -/- -/- -/- -/- na NAD NAD
027 8 16 18 f 182 indiff. na na 2 p.P1007A Cys-rich p.R958Q Cys-rich -/- +/- +/- +/- +/- p.P532L NAD NAD
042 8 26 29 f 91 var. na na 2 p.R978C Cys-rich delX1-X6 - +/+ +/+ +/+ +/+ +/+ na NAD NAD
010 10 12 12 f 60 cl. 29 78 0 NAD - NAD - -/- +/+ +/+ +/+ +/+ na NAD NAD
019 10 14 23 m 130 cl. na na 2 p.I1061T Cys-rich p.I1061T Cys-rich na na na na na na NAD NAD
041 10 21 22 m 231 cl. na na 2 p.Y825C - p.A1054T Cys-rich -/- -/- +/- +/- +/- na NAD NAD
013 11 16 27 m 180 var. na na 1 p.S954L Cys-rich NAD - na na na na na na NAD NAD
020 11 12 32 f 140 var. na na 2 p.P474L - p.I1094T Cys-rich +/- -/- +/- +/- -/- na NAD NAD
014 12 0 23 m 20 na na na 2 p.I1061T Cys-rich p.I1061T Cys-rich +/? na na na na na NAD NAD
015 12 16 23 m 152 cl. na na 2 p.S954L Cys-rich p.W1145R na na na na na na na NAD NAD
018 12 16 25 m 170 na na na 2 p.I1061T Cys-rich p.I1061T Cys-rich na na na na na na NAD NAD
040 12 18 21 m 190 var. na na 2 c.2195insT - p.Y825C - -/- -/- -/- -/- -/- na NAD NAD
043 12 21 23 f 91 var. na na 2 p.R978C Cys-rich delX1-X6 - +/+ +/+ +/+ +/+ +/+ na NAD NAD
021 13 13 31 m 160 na na na 2 p.P474L - p.I1094T Cys-rich na na +/- na na na NAD NAD
033 13 18 21 f 155 na 34 102 2 p.G1162A - p.G1162A - -/- -/- -/- -/- -/- na NAD NAD
030 17 43 46 m 205 cl. 49 106 2 p.S954L Cys-rich p.I1061T Cys-rich ?/? ?/? ?/? ?/? ?/? na NAD NAD
023 41 35 45 m 20 var. 61 200 2 p.N222S - p.I1061T Cys-rich +/- +/- +/- +/- +/- na p.N111K NAD
006 na 2 4 f 60 na 102 262 2 p.H1016L Cys-rich p.I1061T Cys-rich +/- -/- +/- -/- -/- na NAD NAD
009 na 0 0 m 41 cl. na na 2 c.616_619del - p.I1061T Cys-rich -/- -/- -/- -/- -/- na NAD NAD
011 na 0 0 f 81 na na na 2 p.P691S SSD c.2279_2281TCTdel - -/- -/- -/- -/- -/- na NAD NAD
032 na 8 10 m 60 cl. 54 183 2 p.G1162A - p.G1162A - -/- +/+ +/+ +/+ +/+ na NAD NAD
Figure 1 Diagnostic findings in studied NP-C patient cohort (n=42).* NP-C Suspicion Index (acc. to Wijburg et al., 2012): <40, NP-C unlikely;
40-69, NP-C follow up advised; ≥70, NP-C likely; na, not available; NAD, nothing abnormal detected; cl., classic; var., variant; indiff., indifferent;
Cys-rich, cystein-rich loop (aa 855-1098); SSD, sterol sensing domain (aa 615-797), normal range: 3β,5α,6β-triol: 29-152; 7-KC: 78-390.
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Correlation of NPC-cdb score with plasma oxysterol levels
16 individuals of our cohort had been analyzed by Jiang
et al., 2011 [22] for plasma levels of cholestane-3β,5α,6β-
triol (3β,5α,6β-triol) and 7-ketocholesterol (7-KC) (Figure 1).
For all patients mean oxysterol levels (±SD) (from a median
of 2.5 samples per individual) were above suggested cut-off
levels (24.5 for cholestane-3β,5α,6β-triol (3β,5α,6β-triol);
47.5 for 7-ketocholesterol (7-KC)) [range: 3β,5α,6β-triol:
29-152; 7-KC: 78-390]. For 10 of the 16 individuals a total
of 19 blood samples had been obtained at dates for which
also neuro-psychiatric status was scored. For these 10
individuals means for both, plasma oxysterols and NPC-
cdb scores were generated from up to three consecu-
tive measurements per patient, and correlation analysis
was performed by determining linear regression curves
(Additional file 4: Figure S1).
Results
Generation of the NP-C clinical database (NPC-cdb)
With the aim to establish a comprehensive repository
(NPC-cdb) to store, share and analyze diagnostic and clin-
ical findings in NP-C patients, we queried the literature
for symptoms of direct and possible disease-relevance. To
systematically assess whether and when in the course of
disease these symptoms manifest, we designed a question-
naire of 270 questions covering 12 subject areas, including
diagnostics, pre/postnatal development, visceral, neuro-
logical and psychiatric signs, speech and auditory function,
social skills and education, therapy and family history
(Additional file 1). This questionnaire assisted to acquire
longitudinal data in personal interviews that were entered
as fixed terms and/or quantifiable parameters into a cus-
tomizable electronic database (Additional file 2).
Diagnostic findings in 42 patients support the
heterogeneous nature of NP-C
To test the applicability of NPC-cdb, we obtained diagnos-
tic and longitudinal clinical findings from the majority of
NP-C families in Germany and Switzerland. Comprehen-
sive datasets from 42 patients were analyzed, among them
six sib-pairs and one sib-trio (Figure 1). The age of the pa-
tients at time of assessment ranged from newborn to
46 years (mean=17.4±11.2 y) (Figure 2). Eight patients died
since assessment, of them two with hepatic failure and six
in a progressed neurodegenerative state. 34 patients re-
ceived Miglustat (Zavesca©, Actelion Pharmaceuticals) for
treating neurological manifestations [4], however few were
on treatment for more than one year (mean=1.8±1.6 y). Of
the eight untreated patients, five were in a progressed
disease stage, two freshly diagnosed and one did not
show neurological signs. While only a minority of patients
(n=9) reported to take dietary supplements, most received
symptomatic treatment such as physical (n=25) or speech
therapy (n=22).
The mean delay from first neurological symptom to
diagnosis NP-C was 5.7±7.6 years (Figure 1, Figure 2),
supporting data from other cohorts that diagnosing NP-
C is difficult. Of the 26 patients in whom filipin staining
of cultured fibroblasts was performed to support or ex-
clude NP-C as diagnosis, 17 (65%) showed a “classical”
cholesterol storage pattern compatible with NP-C. In
eight patients (31%) filipin staining pattern was “variant”
[3,19,20], and in patients #027 and #029, albeit diagnosed
at a progressed disease stage, even reported as indifferent
to healthy controls. In contrast, all 16 patients (100%)
in which plasma oxysterols had been determined showed
elevated cholestane-3β,5α,6β-triol and 7-ketocholesterol
levels compatible with NP-C.
Molecular analyses of NPC1 and NPC2 genes identi-
fied likely disease-causing homozygous or compound-
heterozygous DNA sequence variants in 36 (86%) patients,
among them one NPC2-patient. In six patients (14%) with
typical clinical and/or biochemical signs of NP-C, sequenc-
ing identified either a single (n=5) or no (n=1; #010) muta-
tions at the known disease loci. Of the in total 80 mutant
alleles, 62 (78%) carried missense variants, two affected
splicing, five introduced a pre-term stop-codon, nine were
deletions and two insertions (Figure 1).
Based on the clinical data acquired, we retrospectively
assessed the likelihood that a patient would have been
considered as NP-C when a recently introduced clinical
Suspicion Index (SI) score [8] would have been applied
at the time of diagnosis. According to this score, testing
for NP-C would have been recommended for only 30
(70%) of our patients (mean±SD SI score: 173±50), and
critical follow-up for 7 (17%; mean±SD SI score: 52±24),
respectively. Remarkably, based on the SI score NP-C
would have been considered as unlikely in five patients
(#002,007,014,023,028) (13%; mean±SD SI score: 16±9)
(Figure 1). Importantly, four of these five patients presented
with isolated splenomegaly or hepatosplenomegaly, while
NP-C typical neurological signs in this subcohort man-
ifested if at all only shortly before diagnosis or later (mean
interval from onset of neurological signs to diagnosis=0.8±
1.8 y). This suggested low sensitivity of the SI score in
patients with predominatly visceral disease or early neuro-
psychiatric disease stages. We tested this hypothesis by
comparing patients with a long delay between first neuro-
logical symptom and diagnosis to patients with a short
disease history (first neurological symptom <3 y before
diagnosis). Indeed, sensitivity of the SI score correlated
negatively with duration of disease (p<3.9x10-4; Fisher’s
exact test). These findings further accentuate the need for
better strategies to identify patients early in the course
of disease, such as 18 patients of our cohort (43%) that
presented with prolonged jaundice and 9 (21%) with iso-
lated organomegaly as neonates, long before typical neuro-
logical NP-C signs manifested.
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Cognitive and coordination deficits are early indicators
of NP-C
One possibility to use longitudinal data acquired through
NPC-cdb is to investigate how neurological disease as the
major disease burden develops in NP-C patients. The ma-
jority of our patients (n=40) developed initial specific or
less specific neuropsychiatric signs before adulthood
(range: 0-41 y; mean=7.9±6.9 y) (Figure 2, Figure 1). At
data assessment, only four patients (two neonates and two
siblings of more severely affected sisters) did not show
neuropsychiatric signs, making neurological involvement
in NP-C equally prevalent as past or present splenomegaly
(90%; n=38). However, while in most patients the exact
onset and evolvement of organomegaly was difficult to
assess, interview data joint with medical records allowed
us to rather precisely reconstruct neurological disease. Of
the 72 neuropsychiatric signs analyzed and consistent with
previous studies [1,4], cognitive impairment (86%), coor-
dination deficits (clumsiness 81%, ataxia 79%, impaired
fine motor skills 79%), dysarthria (81%) and vertical supra-
nuclear gaze palsy (VSGP, 76%) were reported as the most
prevalent neuropsychiatric symptoms (Additional file 5:
Table S1). Using censored Kaplan-Meier curves we mod-
eled the manifestation of all 72 neuropsychiatric symp-
toms over the course of disease. Importantly, cognitive
impairment (3.4 y, 95%CI 2.5-4.3), clumsiness (3.7 y, 95%
CI 1.6-5.9) and impaired fine motor skills (3.4 y, 95%CI
1.6-5.9) were predicted as the earliest signs of neurological
manifestation in our cohort (Figure 3). With this, these
less specific symptoms ranked considerably more early
than VSGP (7.4 y, 95%CI 4.7-10.8), ataxia (7.5 y, 95%CI
4.7-7.4) or dysarthria (6.9 y, 95%CI 4.8-9.1), neurological








Figure 2 Spectrum of disease presentation in studied neurological NP-C patient cohort (n=38). Horizontal bars show disease duration
(in years) in individual patients (represented by NPC-cdb no.; see Figure 1) from the onset of neurological symptoms until the age at data
assessment. Dark blue, timespan from first reported neurological sign until diagnosis NP-C. Light blue, timespan from diagnosis until data
assessment. In four patients NP-C was diagnosed prior to the onset of neurological signs (narrow bars). Deceased patients are highlighted by
crosses. Patients are aligned according to age at diagnosis.
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As the early diagnosis and start of treatment is believed
to benefit treatment outcome in NP-C [8-10], we deter-
mined the manifestation of selected neuropsychiatric signs
relative to the time point of diagnosis (Figure 4). Notably,
once symptoms considered as typical for NP-C were ob-
served in a patient, the delay until diagnosis was short
(mean delay from manifestation to diagnosis: VSGP -1.4±
0.7 y, cataplexy 0.3±1.0 y, dysarthria 0.0±0.7 y). This indi-
cated that the presence of such “classical” NP-C symptoms
either succesfully initiates the right path to diagnosis, or
that these signs are recognized immediately following the
diagnosis NP-C in a patient. By contrast, delay from onset
to diagnosis was long for less specific neuropsychiatric
signs affecting cognition and coordination that in the vast
majority of patients (>79%; Additional file 5: Table S1) was
noticed considerably more early during disease course (e.g.,
clumsiness (-4.9±1.1 y), cognitive impairment (-3.6±1.1 y),
impaired fine motor skills (-2.2±0.9 y), balance problems
(-1.4±1.1 y) (Figure 4). These findings strongly propose that
less specific neuropsychiatric signs are frequent and early
indicators of NP-C, and that raising the awareness of this
may help to substantially reduce the timespan until a pa-
tient is diagnosed.
NP-C progression is variable and likely correlates with
external and/or genetic factors
NP-C manifestation and course appeared to vary consid-
erably within our cohort (Figure 1, Figure 2). Several
scoring systems have been developed to monitor disease
progression in NP-C [10,13,17,23]. However, none of the
existing tools covered the comprehensive patient-specific
clinical information available through NPC-cdb. Moreover,
previous scales quantify deterioration or improvement
within defined symptom domains, which necessitates
complete evaluation of all such domains at each visit. To
ease the acquisition and documentation of comprehensive
longitudinal data, we therefore established a novel clinical
outcome scale (NPC-cdb score). Unlike previous tools,
the NPC-cdb score represents the sum of all past and
current symptoms present in a patient at a given time
point, with each symptom (as listed in Figure 5) contribut-
ing a severity-weighted summand (for guidelines on how
to apply the NPC-cdb score, see Additional file 3). For
10 patients in which plasma oxysterol levels were mea-
sured at visits for which scoring could be performed,
scores correlated well with mean 3β,5α,6β-triol and 7-KC
levels, which supports the hypothesis that the NPC-cdb
Figure 3 Sequence of most frequent neuropsychiatric symptoms during disease course. Estimated median time until presentation (±95%CI) of
the 21 most frequent neurological signs present in >40% of studied neurological patients (n=38), normalized to the relative age at neurological disease
onset (x=0). Symptoms are aligned in order of appearance (bottom to top). VSGP, vertical supranuclear gaze palsy.
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score is a reliable indicator of NP-C severity (Additional
file 4: Figure S1).
We applied the NPC-cdb score to retrospectively as-
sess disease history in each of the 38 patients with
neuropsychiatric signs. Consistent with previous findings
[17], NP-C severity progressed in a close to linear fash-
ion when the overall cohort was considered (Figure 6A;
mean linear regression curve: y=1.83x+8.9; R2=0.96). In-
terestingly, however, and irrespective of whether the
NPC-cdb score or a previously established clinical sever-
ity scale [17] were applied (Figure 6A, inset), disease
progression independent of age of onset varied consider-
ably: While most patients (n=24) progressed gradually
over time (Figure 6B, top), seven patients with early
neurological onset showed a fulminant progression with
all annual NPC-cdb scores above the respective means
of the collective (Figure 6B, center). Moreover, a further
cluster of six patients with initially rather stable disease
revealed a close to three-fold (2.9±1.1) accelerated pro-
gression at a later time point during disease (mean
delay=6.7±2.5 y after neurological onset; Figure 6B, bot-
tom). We questioned what might be possible reasons for
such accelerated deterioration. Based on NPC-cdb, in
four of these six patients seizures had occurred for the
first time in the year preceding the rapid decline, while
the prevalence of seizures in the overall cohort was 35%
(n=15). Indeed, association analysis showed that despite
correction for seizure-associated score points, patients
showed a high likelihood for an accelerated disease pro-
gression within two years upon the first seizure event
(p<7x10-4; Fisher’s exact test). This suggests that the oc-
currence of seizures is predictive for a poor prognosis in
a patient.
We further questioned whether some of the pheno-
typic differences could be due to genetic reasons. How-
ever, due to the still small sample size and large number
of NPC1/NPC2 alleles in our cohort, no significant cor-
relations between genotype at the known NP-C loci and
overall disease progression were reached. However, con-
sistent with previous observations [3] and irrespective of
Figure 4 Manifestation of 10 characteristic neurological NP-C signs relative to diagnosis. Sequence of occurrence of 10 selected neurological
symptoms with diagnostic importance (acc. to Wijburg et al., 2012, [8]), normalized to the relative age at diagnosis (y=0). Each dot represents one
patient. Medians are indicated by grey bars. Symptoms are aligned in order of appearance (bottom to top). VSGP, vertical supranuclear gaze palsy.
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the age of onset, progression of disease was similar be-
tween NP-C siblings who shared the same haplotypes
(Figure 1, Additional file 6: Figure S2), indicating that at
least part of the variability in NP-C progression is asso-
ciated with distinct NPC1- and NPC2-mutations.
Discussion
We have developed the NP-C clinical database (NPC-
cdb) with the aim to provide a unifying framework for
clinical and diagnostic datasets on NP-C from multiple
patient cohorts. A detailed, customized questionnaire facil-
itates to comprehensively obtain current and past medical
history of NP-C patients that can be entered as fixed terms
and/or quantifiable parameters into a decentralized elec-
tronic database. NPC-cdb is intuitive, can be customized
to an individual study’s needs and allows for an easy shar-
ing of distinct, anonymized datasets among researchers
and clinicians from diverse disciplines. We envision NPC-
cdb to become a starting point for large-scale collaborative
studies on NP-C pathogenesis and on the efficiency of
current and future therapies.
As a proof-of-concept, we applied our infrastructure
to retrospectively assess disease progression in 42 NP-C
patients of German and Swiss origin, to date the most
comprehensive survey on NP-C in these countries. We
confirm many of the findings in other cohorts [8,9,12-18],
among them a delay of several years from neurological
onset to diagnosis; difficulties to unambiguously secure
NP-C with current diagnostic tools; or a striking influence
of the age at onset on disease progression. However, sys-
tematic acquisition of the temporal sequence of clinical
signs as assisted by NPC-cdb opens perspectives beyond
this previous knowledge. For instance, while the fre-
quently insidious onset of NP-C is known among experts
[4,17], our data show for the first time in a larger cohort
that unspecific neuropsychiatric signs involving cognitive,
behavioral and motor skills are among the first disease
indicators. Specifically, subtle signs such as clumsiness or
perturbed fine motor skills were noticed in our cohort
close to four years before distinct NP-C indicators such as
VSGP, cataplexy or ataxia were reported. Certainly, our
data do not exclude the possibility that also specific NP-C
signs arise early in the course of disease, but are difficult
to assess (such as impaired saccadic eye movements; [4])
and therefore may simply have been overlooked. More-
over, a substantial fraction of our data was acquired in
Figure 5 Symptoms considered for NP-C clinical database (NPC-cdb) score. Colored areas represent different subject categories in NPC-cdb
questionnaire and database (Additional file 1 and Additional file 2).
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personal interviews with non-expert relatives. As the earli-
est abnormalities reported by close family members are by
nature subjective and often not documented as such in
medical records, we can neither exclude a bias towards
more familiar symptoms nor an interviewer-bias by retro-
spectively asking for the presence of a respective symptom.
Nevertheless, our finding that less specific neuropsychi-
atric signs are early indicators of NP-C is supported by (i.)
the large number of patients from all age groups with a
similar sequence of clinical events and (ii.) a high congru-
ency between interview and chart data for better docu-
mented NP-C symptoms (not shown). Importantly, our
data also show that the occurrence of certain more specific
NP-C signs appeared to pave the way for a diagnosis
within less than 1.4 years after onset of the respective
symptom. Our study therefore strongly suggests that to
accelerate diagnosis, less specific neuropsychiatric signs
should receive a higher attention.
This is of particular importance since even latest diag-
nostic aids to decide which patients should undergo NP-C
testing strongly rely on the presence of the most promi-
nent NP-C signs. For instance, a recently published retro-
spective chart review in a large cohort [8] revealed that
cholestasis, splenomegaly, VSGP, cataplexy, cognitive
decline, co-affected relatives and a co-occurrence of
symptoms from different disease domains are the stron-
gest NP-C predictors. Consequently, a proposed Suspi-
cion Index (SI) tool weighs these symptoms relatively
high, while frequent, but less specific motor coordination,
cognitive and behavioral problems are ranked as moderate
to low indicators. While also our study shows that the SI
tool is very sensitive in identifying patients that have read-
ily apparent disease, it has not been taken into account
during the generation how far in the disease process in in-
dividual patients had already progressed before diagnostic
testing was initiated. Retrospective application of this Sus-
picion Index tool to our collective revealed that at diagno-
sis 30% of our patients would not have been considered as
among the strongest candidates for NP-C testing, while
NP-C would have been regarded even as unlikely in 13%.
Importantly, diagnosis in this sub-cohort was secured be-
fore or early after onset of first neurological symptoms,
which is reflected by a negative correlation between Suspi-
cion Index score and time to diagnosis. With this, our
data take into question that the Suspicion Index tool will
significantly contribute to identify NP-C patients early in
the disease process. Instead, to reduce diagnostic delay
and with this raise response to treatment [8-10], we
propose that less specific NP-C indicators should be in-
cluded in a decision to initiate NP-C testing. This is of
Figure 6 Disease progression in 38 NP-C patients with neurological disease. (A) Occurrence of disease symptoms over time (in years) was
scored for each of the 38 patients (colored lines) individually with both, the NPC-cdb score (large graph) and the NIH clinical severity scale
(Yanyanin et al., 2010, [17]; inset), each normalized to the age at neurological disease onset (x=0). Higher score values (y-axis) reflect higher
number of symptoms. Standard deviations around mean values (reflecting the normal range) are represented by yellow clouds. (B) Examples for
patients with particular types of disease progression. Top, steady disease course; center, rapid degenerative course; bottom, initial steady
progression is followed by acceleration.
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particular relevance as plasma oxysterols as a rapid and
reliable biochemical screening tool may soon enable the
cost-efficient identification of putative NP-C patients from
larger cohorts with diverse clinical backgrounds.
For studying the temporal development of NP-C we
generated the NPC-cdb score, which allowed us to closely
monitor disease progression independent from the age of
onset. Unlike a similarly comprehensive clinical severity
scale [17], determining the NPC-cdb score for a patient
does neither rely on laboratory investigations nor on la-
borious re-evaluation of distinct clinical sub-domains at
each visit. Instead, the sum of all severity-weighted clinical
symptoms present at distinct time points during the
course of disease is determined once from questionnaire
data obtained at one comprehensive data assessment.
During follow-up visits, only symptoms that manifested
since the previous data entry are to be added. This ease of
use should proof useful in clinical settings and with this
complement widely used, but less comprehensive scales
that only poorly reflect the heterogeneous clinical picture
of NP-C [10,12,13,23]. As the NPC-cdb score is in
principle open ended, further symptoms of interest can
easily be added which may be of particular interest for
prospective and interventional studies. Our focus here
was on a solid reconstruction of disease history. Interest-
ingly and in seeming conflict with another cohort where
NP-C severity progressed in a close to linear fashion [17],
a sizable fraction of our patients (n=6; 14%), among them
one sib pair, showed a steep deterioration of abilities after
an initially only slowly-progressive disease. In our cohort
this deterioration was associated with seizures, onset of
which in a patient could signalize progressed neurological
state. Alternatively, seizures might as well impair NP-C
relevant brain functions, which secondarily accelerates
disease progression as reflected by higher NPC-cdb scores.
Closer monitoring of clinical events before and after the
onset of seizures in future studies may help to distinguish
between cause and consequence.
In addition to epilepsy, the existence of further factors
impacting on adverse or beneficial clinical outcomes is
highly probable, but failed to be demonstrated here due
to insufficient patient numbers. Experience from com-
plex diseases propose that much larger, equally well-
documented cohorts will be needed to unambiguously
identify also factors with more subtle impact on disease
expression [24]. This is particularly the case when aiming
at the identification of genetic factors or biomarkers as the
basis for particular NP-C phenotypes that may explain the
heterogeneous nature of the disease. The prospect of
Miglustat as a specific treatment option for NP-C [25] has
triggered numerous trials in several national NP-C patient
cohorts (e.g., [9,10,13-17,23,26]). These studies have con-
tributed significantly to our understanding of which symp-
toms within the NP-C spectrum are frequent and specific.
The systematic collection of comprehensive diagnostic and
longitudinal clinical information in a central database will
further extend and improve the generalizability of findings
from individual cohorts. By providing large-enough patient
numbers this may allow to precisely characterize the
heterogeneous clinical picture and unambiguously test
whether existing or future treatment strategies are effi-
cient. We are confident that NPC-cdb may now provide a
platform for such initiatives.
Additional files
Additional file 1: (e-Questionnaire): NPC-cdb questionnaire.
Additional file 2: (e-Database): NPC-cdb electronic version (based
on Microsoft Office Access, vs. 2010).
Additional file 3: (e-Guidelines): NPC-cdb score guidelines.
Additional file 4: Figure S1. Correlation of NPC-cdb score with plasma
oxysterol levels and filipin phenotype. For 10 NP-C patients from our
cohort, mean plasma levels (±SD) of cholestane-3β,5α,6β-triol (3β,5α,6β-
triol) and 7-ketocholesterol (7-KC) were determined according to Jiang
et al. [22] from a total of 19 samples (with a median of 2.5 samples per
individual) (y-axis). Mean NPC-cdb scores per patient were generated
from phenotypic information acquired at up to three consecutive visits
(x-axis). Higher score values (y-axis) reflect higher number of symptoms.
Where available, “classic” or “variant” filipin staining pattern are
highlighted in grey.
Additional file 5: Table S1. Temporal development of 72
longitudinally-assessed NP-C symptoms (sorted acc. to frequency of
occurrence).
Additional file 6: Figure S2. Disease progression in siblings.
Occurrence of disease symptoms over time (in years) was scored for each
sibling of 3 NP-C sib pairs and one NP-C sib trio with the NPC-cdb score
and normalized to the age at neurological disease onset (x=0). Higher
score values (y-axis) reflect higher number of symptoms. Standard
deviations (reflecting the normal range) are represented by shaded clouds.
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